These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34165783)

  • 1. Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma.
    Bal S; Giri S; Godby KN; Costa LJ
    Br J Haematol; 2021 Oct; 195(1):e113-e116. PubMed ID: 34165783
    [No Abstract]   [Full Text] [Related]  

  • 2. Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
    Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH; Kaufman JL
    Am J Hematol; 2021 Mar; 96(3):E68-E71. PubMed ID: 33275813
    [No Abstract]   [Full Text] [Related]  

  • 3. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).
    Touzeau C; Le Gouill S; Mahé B; Boudreault JS; Gastinne T; Blin N; Caillon H; Dousset C; Amiot M; Moreau P
    Haematologica; 2017 Mar; 102(3):e112-e114. PubMed ID: 28057737
    [No Abstract]   [Full Text] [Related]  

  • 4. Secondary plasma cell leukaemia treated with single agent venetoclax.
    Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
    Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
    [No Abstract]   [Full Text] [Related]  

  • 5. Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.
    Avigan ZM; Joshua Richter Md
    Oncology (Williston Park); 2024 Jun; 38(6):239-241. PubMed ID: 38899981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations.
    Ji M; Jang S; Lee JH; Seo EJ
    Ann Hematol; 2013 Aug; 92(8):1129-31. PubMed ID: 23307601
    [No Abstract]   [Full Text] [Related]  

  • 7. The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene.
    Vaandrager JW; Kluin P; Schuuring E
    Blood; 1997 Jan; 89(1):349-50. PubMed ID: 8978314
    [No Abstract]   [Full Text] [Related]  

  • 8. IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.
    Mao XH; Zhuang JL; Zhao DD; Li XQ; Du X; Hao M; Xu Y; Yan YT; Liu JH; Fan HS; Sui WW; Deng SH; Li CW; Zhao JW; Yi SH; Du CX; Zou DH; Li ZJ; Zhao YZ; Zhan FH; Tai YT; Fang BJ; Song YP; Wang JX; Anderson KC; Qiu LG; An G
    Eur J Haematol; 2020 Sep; 105(3):326-334. PubMed ID: 32421883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A subset of CD20(+) MM patients without the t(11;14) are associated with poor prognosis and a link to aberrant expression of Wnt signaling.
    Liu J; Gu Z; Yang Y; Wendlandt E; Xu H
    Hematol Oncol; 2014 Dec; 32(4):215-7. PubMed ID: 24408089
    [No Abstract]   [Full Text] [Related]  

  • 10. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.
    Touzeau C; Dousset C; Le Gouill S; Sampath D; Leverson JD; Souers AJ; Maïga S; Béné MC; Moreau P; Pellat-Deceunynck C; Amiot M
    Leukemia; 2014 Jan; 28(1):210-2. PubMed ID: 23860449
    [No Abstract]   [Full Text] [Related]  

  • 11. Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.
    Jelinek T; Popkova T; Duras J; Mihalyova J; Kascak M; Benkova K; Plonkova H; Cerna L; Koristek Z; Simicek M; Hajek R
    Hematol Oncol; 2020 Aug; 38(3):412-414. PubMed ID: 32323881
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain.
    Walters DK; Arendt BK; Tschumper RC; Wu X; Jelinek DF
    Exp Hematol; 2018 Jan; 57():42-49.e1. PubMed ID: 29030084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
    Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
    Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.
    Avet-Loiseau H; Gerson F; Magrangeas F; Minvielle S; Harousseau JL; Bataille R;
    Blood; 2001 Nov; 98(10):3082-6. PubMed ID: 11698294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.
    Nishida K; Tamura A; Nakazawa N; Ueda Y; Abe T; Matsuda F; Kashima K; Taniwaki M
    Blood; 1997 Jul; 90(2):526-34. PubMed ID: 9226151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.
    Pawlyn C; Melchor L; Murison A; Wardell CP; Brioli A; Boyle EM; Kaiser MF; Walker BA; Begum DB; Dahir NB; Proszek P; Gregory WM; Drayson MT; Jackson GH; Ross FM; Davies FE; Morgan GJ
    Blood; 2015 Jan; 125(5):831-40. PubMed ID: 25428216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization.
    Finelli P; Fabris S; Zagano S; Baldini L; Intini D; Nobili L; Lombardi L; Maiolo AT; Neri A
    Blood; 1999 Jul; 94(2):724-32. PubMed ID: 10397739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 14q32 chromosomal translocations: a hallmark of plasma cell dyscrasias?
    Avet-Loiseau H; Minvielle S; Mellerin MP; Magrangeas F; Bataille R
    Hematol J; 2000; 1(5):292-4. PubMed ID: 11920205
    [No Abstract]   [Full Text] [Related]  

  • 19. Translocation of the IgH locus is nearly ubiquitous in multiple myeloma as detected by immuno-FISH.
    Boersma-Vreugdenhil GR; Peeters T; Bast BJ; Lokhorst HM
    Blood; 2003 Feb; 101(4):1653. PubMed ID: 12560243
    [No Abstract]   [Full Text] [Related]  

  • 20. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
    Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
    Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.